Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 5/20 | 0.52 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.47 |
| ▸ | REN | P00797 | 3/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3841326 | 1.00 | CAPN1 (0.52) | CAPN1PSMB5RENPSEN1PSEN2 | |
| SCHEMBL21458028 | 0.89 | REN (0.49) | CAPN1RENPSEN1PSEN2APH1B | |
| SCHEMBL3840760 | 0.89 | REN (0.49) | CAPN1RENPSEN1PSEN2APH1B | |
| SCHEMBL21012396 | 0.87 | REN (0.56) | CAPN1RENPSEN1PSEN2APH1B | |
| SCHEMBL21554922 | 0.87 | REN (0.56) | CAPN1RENPSEN1PSEN2APH1B | |
| SCHEMBL21526205 | 0.87 | ALDH1A1 (0.43) | RENPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21526206 | 0.87 | ALDH1A1 (0.43) | RENPSEN1PSEN2APH1BNCSTN | |
| SCHEMBL3838079 | 0.86 | CAPN1 (0.73) | CAPN1RENPSMB1CTSKCTSL | |
| SCHEMBL21526199 | 0.86 | TDP1 (0.48) | — | |
| SCHEMBL1989246 | 0.86 | TDP1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | OSAKA CITY UNIVERSITY (JP) | 2023-12-19 | — | — | US | disclosed |
| EP-3788031-B1 | DIPEPTIDYL KETOAMIDE META-METHOXYPHENYL DERIVATIVES AND USES THEREOF | LANDSTEINER GENMED S L (ES) | 2023-09-27 | — | — | EP | disclosed |
| US-11242312-B2 | Dipeptidyl ketoamide meta-methoxyphenyl derivatives and uses thereof | LANDSTEINER GENMED, S.L. (ES) | 2022-02-08 | — | — | US | disclosed |
| US-20210317075-A1 | DIPEPTIDYL KETOAMIDE META-METHOXYPHENYL DERIVATIVES AND USES THEREOF | LANDSTEINER GENMED, S.L. (ES) | 2021-10-14 | — | — | US | disclosed |
| EP-3564211-A1 | DIPEPTIDYL KETOAMIDE META-METHOXYPHENYL DERIVATIVES AND USES THEREOF | LANDSTEINER GENMED, S.L. (ES) | 2019-11-06 | — | — | EP | disclosed |
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | OSAKA CITY UNIVERSITY (JP) | 2019-10-17 | — | — | US | disclosed |
| CN-103282043-B | Congenital agyria therapeutic agent | OSAKA CITY UNIVERSITY (JP) | 2015-09-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190314320-A1 | COMPOSITION FOR TREATMENT AND/OR PREVENTION OF PERIPHERAL NERVE DISORDER | PMP22, PRPH, NGF | CAPN1 4158/4885PSMB5 1795/4885REN 2031/4885 |
| US-11242312-B2 | Dipeptidyl ketoamide meta-methoxyphenyl derivatives and uses thereof | DPP4, DPP7, DPP3 | CAPN1 25/4885PSMB5 852/4885REN 41/4885 |
| US-20210317075-A1 | DIPEPTIDYL KETOAMIDE META-METHOXYPHENYL DERIVATIVES AND USES THEREOF | DPP4, DPP7, DPP3 | CAPN1 25/4885PSMB5 852/4885REN 41/4885 |
| US-11844776-B2 | Composition for treatment and/or prevention of peripheral nerve disorder | PMP22, PRPH, NGF | CAPN1 4158/4885PSMB5 1795/4885REN 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.